Biomarkers of Prostate Cancer Progression Identified with Biochemical Profiling Technology
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Metabolon, Inc. has announced that the company’s global biochemical profiling technology has been used to identify biomarkers indicative of prostate cancer progression.
The results of the study, conducted with researchers at the University of Michigan, will be published in the February 12 issue of Nature in a paper titled “Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression”.
The study described in the Nature paper was undertaken to better understand and profile the metabolic changes associated with prostate cancer progression. Using Metabolon’s biochemical profiling to generate global, non-targeted metabolic analysis of tissue, urine, and plasma samples, the researchers were able to identify a series of metabolites (including sarcosine) that are key potential predictors of cancer aggressiveness.
Applying the biomarkers identified in this study, under exclusive license from the University of Michigan, Metabolon plans to make available a research tool for investigators to better understand tumor aggressivity in prostate cancer and other cancers.
“Gaining mechanistic understanding of a disease is the key to discovering new diagnostics,” said John Ryals, chief executive with Metabolon. “The exciting results of this study are an example of just how valuable metabolomic profiling is in the identification of biomarkers.”
The results of the study, conducted with researchers at the University of Michigan, will be published in the February 12 issue of Nature in a paper titled “Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression”.
The study described in the Nature paper was undertaken to better understand and profile the metabolic changes associated with prostate cancer progression. Using Metabolon’s biochemical profiling to generate global, non-targeted metabolic analysis of tissue, urine, and plasma samples, the researchers were able to identify a series of metabolites (including sarcosine) that are key potential predictors of cancer aggressiveness.
Applying the biomarkers identified in this study, under exclusive license from the University of Michigan, Metabolon plans to make available a research tool for investigators to better understand tumor aggressivity in prostate cancer and other cancers.
“Gaining mechanistic understanding of a disease is the key to discovering new diagnostics,” said John Ryals, chief executive with Metabolon. “The exciting results of this study are an example of just how valuable metabolomic profiling is in the identification of biomarkers.”
